American Association for Cancer Research
Browse
crc-22-0517_fig1.png (138.49 kB)

FIGURE 1 from A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors

Download (138.49 kB)
figure
posted on 2023-05-24, 14:20 authored by Shaun D. Fontaine, Christopher W. Carreras, Ralph R. Reid, Gary W. Ashley, Daniel V. Santi

PEG-Exa remaining over time at 37°C at pH 5.0–8.4.

Funding

n/a

History

ARTICLE ABSTRACT

A circulating conjugate that slowly releases Exa is described. It is efficacious after a single dose and synergistic with ATR and PARP inhibitors.

Usage metrics

    Cancer Research Communications

    Categories

    Keywords

    Breast CancerDna Damage And RepairDNA damageSmall Molecule AgentsTopoisomerase agentsChemotherapyCombination chemotherapyPharmacologyPharmacokinetics and pharmacodynamics

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC